Abstract: Pharmaceutical compositions for the treatment of a viral infection by a type-A influenza virus are provided. The compositions include a compound having the property of acting as an inhibitor of the attachment of the viral RNA to the nucleoprotein of the type-A influenza virus, the compound having the property of binding to the binding domain of the viral RNA to the nucleoprotein. Methods of treating an infection by influenza virus by administering an effective amount of the compound to a subject are also disclosed. A process for identifying a compound having the property of binding to the binding domain of the viral RNA to the nucleoprotein of the type-A influenza viruses are further disclosed.

Abstract: A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described.

Abstract: A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described.

Abstract: The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.

Abstract: The invention concerns compounds of formula (I), wherein —XmR1 and YnR2, identical or different are present, or one of the XmR1 or YnR2 is absent and YaR2, identical or different, is present, and in that case the bond between C1 and C2 is a double bond, XmR1 and YnR2 together represent a group A and in that case the bond between C1 and A is a double bond, or their pharmaceutically acceptable salts as medicine.